• Avalo Therapeutics Chief Medical Officer Doyle Mittie reported option exercises on June 30, 2026, acquiring 4,654 common shares at $12.65 and $8.04.
• Mittie also sold 4,654 common shares at $20 on the same date.
• Beneficial ownership in common stock stood at 51,776 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001918845-26-000022), on July 02, 2026, and is solely responsible for the information contained therein.